title: [Recommendations for the prevention of respiratory syncytial virus infection].
abstract: Premature babies < or = 35 weeks gestation, with or without chronic lung disease (CLD), and infants affected by severe congenital heart disease should be considered high risk population for RSV infection and hospitalization. Hygienic measures and RSV monoclonal antibodies (palivizumab) have been found useful in decreasing rates of RSV hospitalization in these patients. Guidelines for their administration include: a) strongly recommended use in premature babies < or = 28 weeks gestation, or born between 29-32 weeks gestation and less than 6 months at start of RSV station or discharged along it, or affected by CLD in treatment during last 6 months or by severe congenital heart disease. Last two groups could be prophylaxed for two RSV seasons. b) Recommended use among premature babies between 32-35 weeks gestation and less than 6 months of age and presenting two or more risk factors: chronologic age < 10 weeks at start of RSV station, breastfeeding < or = 2 months (physician prescription), sibling < 14 years old, day-care assistance, family history of wheezing, > or = 4 adults at home, airways malformation or neuromuscular disease.
authors.affiliation: Hospital Clínic, Institut Clínic de Ginecología, Obstetricia y Neonatología, Universitat de Barcelona, Spain. jfiguer@clinic.ub.es
authors.forename: J
authors.initials: J
authors.lastname: Figueras Aloy
authors.forename: J
authors.initials: J
authors.lastname: Quero
authors.forename: E
authors.initials: E
authors.lastname: Doménech
authors.forename: M C
authors.initials: MC
authors.lastname: López Herrera
authors.forename: I
authors.initials: I
authors.lastname: Izquierdo
authors.forename: A
authors.initials: A
authors.lastname: Losada
authors.forename: J
authors.initials: J
authors.lastname: Perapch
authors.forename: M
authors.initials: M
authors.lastname: Sánchez-Luna
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000517:prevention & control; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab